SPECIAL NOTICE
65 -- Lease ION ENDOLUMINAL ROBOTIC ENDOSCOPY SYSTEM Sole Source
- Notice Date
- 5/26/2023 10:51:00 AM
- Notice Type
- Special Notice
- NAICS
- 339112
— Surgical and Medical Instrument Manufacturing
- Contracting Office
- 246-NETWORK CONTRACTING OFFICE 6 (36C246) HAMPTON VA 23667 USA
- ZIP Code
- 23667
- Solicitation Number
- 36C24623Q0870
- Archive Date
- 05/29/2023
- Point of Contact
- John P Harmsen, Contract Specialist, Phone: 757-722-7961
- E-Mail Address
-
john.harmsen@va.gov
(john.harmsen@va.gov)
- Awardee
- null
- Description
- VHAPG Part 813.106 Simplified Acquisition Procedures: Soliciting from a Single Source Attachment 1: Single Source Justification for Over MPT under the SAT Last Updated: 02/01/22 Page 1 of 1 DEPARTMENT OF VETERANS AFFAIRS Justification for Single Source Awards IAW FAR 13.106-1 Acquisition Plan Action ID: 36C24623AP4377 Contracting Activity: Department of Veterans Affairs, VISN 06, 637, Charles Geoge VA Medical Center, NCO-6 Brief Description of Supplies/ Services required and the intended use/Estimated Amount: 12 month lease of the Intuitive Ion Endoluminal robotic Endoscopy System for evaluating patients with or suspected lung cancer. $17,000.00 / month; $204,000 total cost. Unique characteristics that limit availability to only one source, with the reason no other supplies or services can be used: The Ion Endoluminal Bronchoscopy System allows for high accuracy navigation to a lung lesion and has the ability to stay securely in place for biopsies and treatment modalities . This unit will achieve a higher yield in biopsies (up to 97% from current rate of 60-70%). This will decrease the amount of second procedures and associated complications. Also this unit allows for ablation of tumors via the Navigation System s working channel, where Intuitive is currently the sole proprietor in the USA. The technology associated with this syttem is proprietary, patened, and considered an industrial trade secret which limits the procurement to a sole vendor who does not authorize any other vendors to disteibute the equipment. Lung cancer is the leading cause of cancer deaths worldwide. More patients die every year from lung cancer than from prostate, breast, and colon cancer combined. The majority of patients diagnosed with lung cancer do not survive, largely,in part, because the disease has often progressed to a more advanced stage at the time of diagnosis. Nodule location and size combined with technology limitations have made early-stage diagnosis of lung cancer challenging. With the ability for early detection of nodule location and size of the Ion Endoluminal platform, and the reduced rate of pneumothoraxes requiring inpatient hospital stays after percutaneous biopsies, it is imperative to bring this capability into the medical center as soon as feasible. Due to the outright purchase cost requiring the acquisition to follow the lengthy Capital Investment Board (CIB) process, the CGVAMC seeks to lease the system for a base period of 12 months with the intent to purchase the system once approval and funding has been approved through that process. Description of market research conducted and results or statement why it was not conducted: Due to the proprietary, patent, and copywrite nature and costs associated with the equipment and support functions it requires, it is unlikely competition would be expanded in a reasonable period of time. Contracting Officer's Certification: Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. John Harmsen Contracting Officer
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/85ab72a59b364a409f0496945cdd95ec/view)
- Record
- SN06695915-F 20230528/230526230105 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |